A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03661320.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationBristol-Myers Squibb

• Primary IDCA017-078
• Secondary IDsNCI-2019-00898, 2017-004692-31, 2024-512158-12
• ClinicalTrials.gov IDNCT03661320